

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

## **ANNOUNCEMENT ON SPECIAL DIVIDEND**

Reference is made to the prospectus of China Resources Pharmaceutical Group Limited (the “**Company**”) dated 17 October 2016 in relation to, among other things, a special pre-listing dividend distribution plan of the Company (the “**Special Dividend**”) and the announcement dated 12 December 2017 in relation to the declaration and payment of 30% of the Special Dividend (the “**Announcement**”). Unless stated otherwise herein, capitalized terms used herein shall have the same meaning as those defined in the Announcement.

The Board hereby announces that, taking into account the distributable profits attained by the Company, the Board has resolved to declare the remaining 70% of the Special Dividend in the amount of HK\$1,559,479,408.50, of which HK\$1,122,825,174.12 and HK\$436,654,234.38 will be distributed to CRH (Pharmaceutical) and BSCOMC Investment and Management Co., Limited (“**BSCOMC Investment**”, formerly known as Beijing Pharmaceutical Investment Limited) in the proportion of 72% and 28%, respectively, pursuant to the Special Dividend Shareholders’ Resolution.

It is expected that such Special Dividend will be paid to CRH (Pharmaceutical) and BSCOMC Investment by no later than 26 October 2018 pursuant to the Special Dividend Shareholders’ Resolution, and the payment of such Special Dividend will be funded by cash resources of the Group, including distributions from the subsidiaries of the Company and external financing (other than the net proceeds from the global offering of the Company).

By order of the Board

**China Resources Pharmaceutical Group Limited**

**WANG Chuncheng**

*Executive Director*

Beijing, 18 October 2018

*As of the date of this announcement, the Board comprises Mr. FU Yuning as chairman and non-executive Director, Mr. WANG Chuncheng and Mr. LI Guohui as executive Directors, Mr. CHEN Rong, Mr. YU Zhongliang, Mr. WANG Shouye and Mr. LU Ruizhi as non-executive Directors, Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.*